![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Gives Nod to Alexion's Strensiq for Narrow Use
NICE Gives Nod to Alexion's Strensiq for Narrow Use
February 15, 2017
The UK’s drug pricing watchdog recommended that the National Health Service only reimburse Alexion’s bone drug Strensiq for the treatment of perinatal- and infantile-onset hypophosphatasia, provided the company delivers the discounted price as promised.
The UK’s National Institute for Health and Care Excellence declined to back the drug for juvenile-onset disease, citing the high cost of the treatment and the uncertainty surrounding its long-term benefits.
A standard course of treatment costs £366,912 (US $460,195) per patient. The company agreed to discount the price for an undisclosed amount, NICE said.
Upcoming Events
-
21Oct